IN THE CLAIMS:

Cancel all previous pending claims without prejudice.

Add the following new claims:

SUB E1

1-20. (new) A cell composition comprising macrophages, wherein said macrophages are present in an amount of about 10 to about 70%, said percentage being expressed with respect to the total number of cells, and wherein said composition exhibits anti-infectious and hematopoietic properties.

21. (new) The cell composition according to claim 20, further comprising progenitor cells, said progenitor cells are present in an amount of at lesat 0.1%, said percentage being expressed with respect to the total number of cells.

SUB E2

22. (new) The cell composition according to claim 20, further comprising progenitor cells, said progenitor cells are present in an amount of about 0.1 to about 20%, said percentage being expressed with respect to the total number of cells.

23. (new) The cell composition according to claim 20, further comprising myeloid cells, said myeloid cells are present

in an amount of about 10% to about 30%, said percentage being expressed with respect to the total number of cells.

24. (new) The cell composition according to claim 20, further comprising myeloid cells and progenitor cells, said progenitor cells are present in an amount of at least about 0.1%, said myeloid cells are present in an amount of about 10% to about 30%, said percentages are expressed with respect to the total number of cells.

25. (new) The cell composition according to claim 20, further comprising T lymphocytes in an amount of about 10 to 60% expressed with respect to the total number of cells.

SUB E 3

26. (new) The cell composition according to claim 21, wherein said progenitor cells contain from about 0.1 to about 20% of stem cells, expressed with respect to the total number of progenitor cells.

27. (new) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 20.

28. (new) The cell composition according to claim 20, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells, and
- from about 0.1 to about 20% of stem cells.

29. (new) The cell composition according to claim 22, further comprising T lymphocytes, in an amount of about 10 to 60% expressed with respect to the total number of cells.

30. (new) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 22.

31. (new) The cell composition according to claim 22, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells, and
- from about 0.1 to about 20% of stem cells.

--32. (new) A cell composition comprising macrophages, myeloid cells and progenitor cells, said progenitor cells are present in an amount of about 0.1% to about 20%, said macrophages are in an amount of about 10 to about 70%, and said percentages are expressed with respect to the total number of cells, as obtained by a process comprising the following steps:

- collecting mononuclear cells and progenitors by apheresis

- co-culturing blood mononuclear cells and progenitors, after washing of platelets, granulocytes and erythrocytes, for 4 to 10 days, in a medium allowing differentiation of monocytes into macrophages and myeloid progenitors into polynuclear cells.

--33. (new) A cell composition comprising macrophages, myeloid cells and progenitor cells, wherein said progenitor cells are present in an amount of about 0.1% to about 20%, said macrophages being in an amount of about 10 to about 70%, said percentages are expressed with respect to the total number of cells, as obtained by a process comprising the following steps:

- mobilizing progenitor cells in the blood of a patient by premedication of said patient with G-CSF and/or GM-CSF or G-CSF and cyclophosphamide,

- collecting mononuclear cells and progenitors by apheresis,